



ASX Announcement (430)

20 July 2011

**Appendix 3B – Registration of Ordinary Shares**  
**Appendix 3Y – Change of Director's Interests**

Please find attached a copy of the Appendix 3B released to the market.

Key points of the issue are:

- **22,897,442** fully Paid Ordinary Shares upon completion of the 1 for 2 Rights Offer; and
- **8,161,114** fully Paid Ordinary Shares upon settlement of the Director Deferred Remuneration in accordance with shareholder approvals of 24 June 2011.

As a result there are now **213,808,896** fully Paid Ordinary Shares in the Company on issue and **7,890,227** VHLG Convertible Notes outstanding.

Yours sincerely,

**John Morrison**  
**Company Secretary**  
**Virax Holdings Limited**

# Appendix 3B

## Application for quotation of additional securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

**Virax Holdings Limited**

ABN

**56 006 569 106**

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	(i) Ordinary Fully Paid Shares (ii) Ordinary Fully Paid Shares
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	(i) 22,897,442 Fully Paid Ordinary Shares (ii) 8,161,114 Fully Paid Ordinary Shares
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	(i) 2.2 cents per ordinary share in accordance with the Rights Offer. Rank equally with existing ordinary issued shares; (ii) 2.304 cents per ordinary shares in accordance with 24 June 2011 shareholder approval.
4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?  If the additional securities do not rank equally, please state: <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	(i) Fully Paid ordinary shares rank pari passu with existing shares (ii) Fully Paid ordinary shares rank pari passu with existing shares
5	Issue price or consideration	(i) 2.2 cents per ordinary share; (ii) 2.304 cents per ordinary share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	(i) Issued pursuant to the 1 for 2 Rights Offer of 25 May 2011; (ii) Issued in settlement of deferred director remuneration as approved by shareholders on 24 June 2011.

7	Dates of entering *securities into uncertificated holdings or despatch of certificates	20 July 2011	
8	Number and *class of all *securities quoted on ASX (including the securities in clause 2 if applicable)	Number	+Class
		213,808,896	Fully Paid Ordinary Shares (VHL)
		7,890,227	Convertible Notes (VHLG)
9	Number and *class of all *securities not quoted on ASX (including the securities in clause 2 if applicable)	Number	+Class
		3,491,333	Unlisted Options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	<p>Fully Paid Ordinary shares rank pari passu with existing shares</p> <p>Note and Option holders are not entitled to Dividends. Upon conversion/exercise the shares rank Pari Passu with existing shares.</p>	

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	<p>Note: Security holders must be told how their entitlements are to be dealt with.</p> <p>Cross reference: rule 7.7.</p>	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Despatch date	N/A

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35  If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
 1 - 1,000  
 1,001 - 5,000  
 5,001 - 10,000  
 10,001 - 100,000  
 100,001 and over
- 37  A copy of any trust deed for the additional +securities

**Entities that have ticked box 34(b)**

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?  
  
 If the additional securities do not rank equally, please state:  
 • the date from which they do  
 • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  
 • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now  
  
 Example: In the case of restricted securities, end of restriction period  
  
 (if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

## Quotation agreement

- 1 Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:

(Director/Company Secretary)

Date: 20 July 2011

Print name:

John Morrison

**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 06**

<b>Name of entity:</b>	Virax Holdings Limited
<b>ABN No:</b>	56 006 569 106

We, Virax Holdings Limited, give ASX the following information under listing rule 3.19A.1 and as agent for the Director for the purposes of section 205G of the Corporation Act.

<b>Name of Director</b>	Michael Humphris	
<b>Date of last notice</b>	29 November 2010	<b>Last Notice No.</b> 5

**Part 1 – Change of Director's relevant interest in securities\***

<b>Direct or indirect interest</b>	<b>Direct</b>		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest			
<b>Date of change</b>	<b>19 July 2011</b>		
<b>Class</b>	Fully Paid Ordinary Shares - VHL	Convertible Notes	Unlisted Options
<b>No. of securities held prior to change</b>	3,269,444	Nil	1,500,000
<b>Number acquired</b>	2,661,374 <sup>A</sup> 1,730,557 <sup>B</sup>		
<b>Number disposed</b>			500,000 <sup>C</sup>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$ 61,312.50 <sup>A</sup> \$ 38,072.25 <sup>B</sup>		
<b>No. of securities held after change</b>	7,661,375	Nil	1,000,000
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Note A: <i>Issued pursuant to Resolution 2, passed at Virax's General Meeting held on 24 June 2011 - Ordinary Shares (VHL) issued in consideration for \$61,312.50 of deferred Directors fees.</i></p> <p>Note B: <i>Acquisition pursuant to 1 for 2 Rights Offer – 25 May 2011</i></p> <p>Note C: <i>Lapsed on 30 June 2011.</i></p>		


**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 06**

**Part 2 – Change of Director's interests in contracts\***

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change:</b>  Note: Details are only required for a contract in relation to which the interest has changed.	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation	
<b>Interest after change</b>	

**If insufficient space please provide attachment and insert attachment number in appropriate space.**

Signed



Date 20 July 2011

\_\_\_\_\_  
John Morrison  
Company Secretary  
Virax Holdings Limited



**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 07**

<b>Name of entity:</b>	Virax Holdings Limited
<b>ABN No:</b>	56 006 569 106

We, Virax Holdings Limited, give ASX the following information under listing rule 3.19A.1 and as agent for the Director for the purposes of section 205G of the Corporation Act.

<b>Name of Director</b>	Ian Pyman	
<b>Date of last notice</b>	29 November 2010	<b>Last Notice No.</b> 6

**Part 1 – Change of Director's relevant interest in securities\***

<b>Direct or indirect interest</b>	<b>Indirect</b>		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest	IP Projects Pty Ltd (as trustee for the Pyman Family Superannuation Fund)		
<b>Date of change</b>	<b>19 July 2011</b>		
<b>Class</b>	Fully Paid Ordinary Share – VHL	Convertible Notes	Unlisted Options
<b>No. of securities held prior to change</b>	2,286,683	Nil	1,125,000
<b>Number acquired</b>	1,951,674 <sup>A</sup> 1,143,342 <sup>B</sup>		
<b>Number disposed</b>			375,000 <sup>C</sup>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$ 44,962.50 <sup>A</sup> \$ 25,153.52 <sup>B</sup>		
<b>No. of securities held after change</b>	5,381,699	Nil	750,000
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Note A: Issued pursuant to Resolution 3, passed at Virax's General Meeting held on 24 June 2011 - Ordinary Shares (VHL) issued in consideration for \$44,962.50 of deferred Directors fees.</p> <p>Note B: Acquisition pursuant to 1 for 2 Rights Offer – 25 May 2011.</p> <p>Note C: Lapsed on 30 June 2011.</p>		

**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 02**

<b>Name of entity:</b>	Virax Holdings Limited
<b>ABN No:</b>	56 006 569 106

We, Virax Holdings Limited, give ASX the following information under listing rule 3.19A.1 and as agent for the Director for the purposes of section 205G of the Corporation Act.

<b>Name of Director</b>	Tim James Cooper	
<b>Date of last notice</b>	29 November 2010	<b>Last Notice No.</b> 1

**Part 1 – Change of Director's relevant interest in securities\***

<b>Direct or indirect interest</b>	<b>Direct</b>		
<b>Nature of direct interest</b> (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest			
<b>Date of change</b>	<b>19 July 2011</b>		
<b>Class</b>	Fully Paid Ordinary Shares	Convertible Notes	Unlisted Options
<b>No. of securities held prior to change</b>	672,839	Nil	1,062,500
<b>Number acquired</b>	1,951,674 <sup>A</sup> 336,420 <sup>B</sup>		
<b>Number disposed</b>			312,500 <sup>C</sup>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$ 44,962.50 <sup>A</sup> \$ 7,401.24 <sup>B</sup>		
<b>No. of securities held after change</b>	2,960,933	Nil	750,000
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Note A: <i>Issued pursuant to Resolution 4, passed at Virax's General Meeting held on 24 June 2011 - Ordinary Shares (VHL) issued in consideration for \$44,962.50 of deferred Directors fees.</i></p> <p>Note B: <i>Acquisition pursuant to 1 for 2 Rights Offer – 25 May 2011.</i></p> <p>Note C: <i>Lapsed on 30 June 2011.</i></p>		

**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 02**

<b>Direct or indirect interest</b>	<b>Indirect</b>		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest	Unaval Nominees Pty Ltd (Unaval Retirement Fund A/C)		
<b>Date of change</b>	<b>19 July 2011</b>		
<b>Class</b>	Fully Paid Ordinary Shares	Convertible Notes	Unlisted Options
<b>No. of securities held prior to change</b>	11,221,106	Nil	1,500,000
<b>Number acquired</b>	5,610,553 <sup>B</sup>		
<b>Number disposed</b>			1,500,000 <sup>D</sup>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$ 123,432.16 <sup>B</sup>		
<b>No. of securities held after change</b>	16,831,659	Nil	Nil
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Note B. <i>Acquisition pursuant to 1 for 2 Rights Offer – 25 May 2011.</i></p> <p>Note D. <i>Lapsed – December 2010.</i></p>		


**Notice of Change of Director's Interest  
(Appendix 3Y Notice)  
Notice No. 02**

**Part 2 – Change of Director's interests in contracts\***

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change:</b>  Note: Details are only required for a contract in relation to which the interest has changed.	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation	
<b>Interest after change</b>	

\* If insufficient space please provide attachment and insert attachment number in appropriate space.

Signed



Date 20 July 2011

\_\_\_\_\_  
John Morrison  
Company Secretary  
Virax Holdings Limited